Egalet Corp (EGLT) 10.10 $EGLT
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
GlobeNewswire - Thu Sep 11, 7:13AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's product candidates and the Company's proprietary Guardian Technology. The following patents were issued:
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, at PAINWeek 2014 in Las Vegas September 2 to 6.
Falling Earnings Estimates Signal Weakness Ahead for Egalet (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:46AM CDT
Egalet has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Tue Aug 12, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today reported business highlights and financial results for the three months ended June 30, 2014.
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001
GlobeNewswire - Wed Aug 06, 5:01AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that we have top-line results from two of the three bioequivalence (BE) studies of Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Egalet to Present at the Canaccord Genuity Growth Conference on August 13
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Canaccord Genuity Growth Conference on Wednesday, August 13, 2014, at 4:00 p.m. EDT. The conference will be held at the InterContinental Hotel in Boston, MA. The presentation will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts.
Egalet to Host Conference Call and Webcast to Discuss Second Quarter Financial Results on August 12, 2014
PR Newswire - Tue Jul 29, 8:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update.
Egalet Appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the appointment of Jeffrey M. Dayno, M.D. as chief medical officer (CMO). Dr. Dayno will be responsible for leading Egalet's clinical development programs as well as overseeing the activities in regulatory affairs, pharmacovigilance and medical affairs. Dr. Dayno will begin July 31.
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical and Chemical Manipulation
GlobeNewswire - Tue Jul 15, 7:38AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced positive results from the Category 1 abuse deterrence study for Egalet-001, an abuse-deterrent, extended-release, oral morphine-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The purpose of this study was to perform a comprehensive, laboratory assessment of physical and chemical manipulation of Egalet-001 and MS Contin(R) (morphine sulfate controlled-release) ("MS Contin" based on Category 1 guidelines presented in the Food and Drug Administration's ("FDA" 2013 draft guidance.
Egalet to Present at the 13th Annual Needham Healthcare Conference on April 9
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that Bob Radie, president and chief executive officer, is scheduled to present next week at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 2:20 p.m. EDT. The conference will be held at the Westin NY Grand Central Hotel.
Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" , a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications, announced today that it was added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes as part of Russell Investments' first quarter IPO additions. The change to the indexes took effect at the close of the U.S. markets yesterday Monday, March 31, 2014.
Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet's proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API).
Egalet Reports Full Year 2013 Financial Results and Provides Business Update
PR Newswire - Wed Mar 26, 6:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company.
Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates
GlobeNewswire - Thu Sep 11, 7:13AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's product candidates and the Company's proprietary Guardian Technology. The following patents were issued: Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, at PAINWeek 2014 in Las Vegas September 2 to 6. Falling Earnings Estimates Signal Weakness Ahead for Egalet (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:46AM CDT
Egalet has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Nasdaq stocks posting largest percentage decreases
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Tue Aug 12, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today reported business highlights and financial results for the three months ended June 30, 2014. Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001
GlobeNewswire - Wed Aug 06, 5:01AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that we have top-line results from two of the three bioequivalence (BE) studies of Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet to Present at the Canaccord Genuity Growth Conference on August 13
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Canaccord Genuity Growth Conference on Wednesday, August 13, 2014, at 4:00 p.m. EDT. The conference will be held at the InterContinental Hotel in Boston, MA. The presentation will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts. Egalet to Host Conference Call and Webcast to Discuss Second Quarter Financial Results on August 12, 2014
PR Newswire - Tue Jul 29, 8:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. Egalet Appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer
GlobeNewswire - Mon Jul 28, 7:41AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the appointment of Jeffrey M. Dayno, M.D. as chief medical officer (CMO). Dr. Dayno will be responsible for leading Egalet's clinical development programs as well as overseeing the activities in regulatory affairs, pharmacovigilance and medical affairs. Dr. Dayno will begin July 31. Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical and Chemical Manipulation
GlobeNewswire - Tue Jul 15, 7:38AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced positive results from the Category 1 abuse deterrence study for Egalet-001, an abuse-deterrent, extended-release, oral morphine-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The purpose of this study was to perform a comprehensive, laboratory assessment of physical and chemical manipulation of Egalet-001 and MS Contin(R) (morphine sulfate controlled-release) ("MS Contin" based on Category 1 guidelines presented in the Food and Drug Administration's ("FDA" 2013 draft guidance. Egalet to Present at the 13th Annual Needham Healthcare Conference on April 9
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that Bob Radie, president and chief executive officer, is scheduled to present next week at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 2:20 p.m. EDT. The conference will be held at the Westin NY Grand Central Hotel. Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
, a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications, announced today that it was added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes as part of Russell Investments' first quarter IPO additions. The change to the indexes took effect at the close of the U.S. markets yesterday Monday, March 31, 2014. Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet's proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API). Egalet Reports Full Year 2013 Financial Results and Provides Business Update
PR Newswire - Wed Mar 26, 6:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company. 
